This system has been widely used to assess its efficacy in providing insulin for type 1 and type 2 diabetes.[1] Conventional insulin treatments pose risks of hypoglycemia and inadequate glycemic control when insulin doses fail to match the patient's fluctuating glucose levels.[24] In contrast, emerging glucose‐responsive insulin delivery systems offer targeted and more efficient insulin administration by reacting directly to changes in blood glucose. The gene discussed is INS; the disease is Hypoglycemia.